We recently published a list of 10 Stocks With At Least $20 Million In Insider Spending Recently. In this article, we are ...

Guggenheim initiated coverage of Sionna Therapeutics (SION) with a Buy rating and $45 price target The firm has a positive view of NBD1 ...

With accurate diagnosis, personalised treatment, and proper medical guidance, many men with genetic infertility can achieve fatherhood and experience the joy of parenthood., Health News - Times Now ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR technologies in the field of ...

Researchers from the Organoid group at the Hubrecht Institute have found that specific gut cells, BEST4/CA7+ cells, regulate electrolyte and water ...

A live webcast of the presentation will be available the day of the event on the “Events” page within the Investors section of Sionna’s website at https://investors.sionnatx.com/. A replay will be ...

Objective: Intestinal current measurement (ICM) provides a sensitive bioassay for assessment of cystic fibrosis transmembrane conductance regulator (CFTR) function in rectal biopsies ex vivo and is ...

I am equally pleased to announce that Duncan McKechnie ... The U.S. launch is underway for ALYFTREK, the fifth Vertex CFTR modulator regimen, while we are also working to secure approval in ...

Sionna’s portfolio is aimed at drugging the cystic fibrosis transmembrane conductance regulator (CFTR) protein, mutations in which are the main cause of the disease. Sionna’s drugs in development all ...

It expanded the use of TRIKAFTA to target another huge batch of non-F508del CFTR mutations in Cystic Fibrosis ... and it expresses my own opinions. I am not receiving compensation for it (other ...

High-throughput screens for small molecules that are effective in “correcting” the functional expression of F508del-CFTR have yielded several promising hits. Two such compounds are currently in ...